Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
Hardman & Co Research: Tissue Regenix (TRX): Funded through to profitability
eqs_en 
0 07.10.20
Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
Edison Investment Research Limited: Oxford Biomedica (OXB): Vector innovation key to cell and gene evolution
eqs_en 
0 05.10.20
Hardman & Co Research: Diurnal (DNL): And then there were three
Hardman & Co Research: Diurnal (DNL): And then there were three
Hardman & Co Research: Diurnal (DNL): And then there were three
eqs_en 
0 30.09.20
Hardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
Hardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
Hardman & Co Research: Diurnal Group (DNL): Closely watching the regulators
eqs_en 
0 17.09.20
Hardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
Hardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
Hardman & Co Research: Diurnal Group (DNL): Q&A with Dr Martin Hall
eqs_en 
0 20.08.20
Hardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
Hardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
Hardman & Co Research: Diurnal Group (DNL): Flow of regulatory approvals
eqs_en 
0 13.08.20
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
eqs_en 
0 20.07.20
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc (Replacement)
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc (Replacement)
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc (Replacement)
eqs_en 
0 11.06.20
Edison Inv Research Limited: Edison issues flash on Ergomed (ERGO)
Edison Inv Research Limited: Edison issues flash on Ergomed (ERGO)
Edison Inv Research Limited: Edison issues flash on Ergomed (ERGO)
eqs_en 
0 10.06.20
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma PLC
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma PLC
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma PLC
eqs_en 
0 09.06.20
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc
Form 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc
eqs_en 
0 22.04.20
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
eqs_en 
0 17.04.20
Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
Hardman & Co Research: Diurnal (DNL): $52.5m US deal strengthens balance sheet further
eqs_en 
0 30.03.20
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
Edison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
eqs_en 
0 25.03.20
Edison Investment Research Limited: Edison issues initiation on Ergomed (ERGO)
Edison Investment Research Limited: Edison issues initiation on Ergomed (ERGO)
Edison Investment Research Limited: Edison issues initiation on Ergomed (ERGO)
eqs_en 
0 25.03.20
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
eqs_en 
0 09.03.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 28.02.20
Hardman & Co Research: Diurnal (DNL): . and more to come (news flow)
Hardman & Co Research: Diurnal (DNL): . and more to come (news flow)
Hardman & Co Research: Diurnal (DNL): . and more to come (news flow)
eqs_en 
0 28.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 27.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 26.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 25.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 24.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 21.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 19.02.20
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
Form 8.3 - The Vanguard Group, Inc.: NMC Health plc
eqs_en 
0 17.02.20